针对儿童IgA脏病的免疫抑制疗法
Areefa Alladin1,2, Deirdre Hahn3, Elisabeth M Hodson4
1Departments of Paediatrics and Community Health Sciences, University of Calgary, Calgary, Canada.
The Cochrane database of systematic reviews
|June 12, 2024
概括
这次审查发现,没有足够的证据表明,像类固醇这样的免疫抑制疗法可以改善IgA脏病 (IgAN) 的儿童的功能或减少蛋白尿. 需要更多高质量的研究来指导儿科IgAN的治疗决策.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 儿科脏病学 儿科脏病学
- 免疫学 免疫学 免疫学
背景情况:
- IgA脏病 (IgAN) 是最常见的原发性血球炎,其特点是异质呈现和显著的发病率.
- 很大一部分患有Igan的儿童在10年内经历功能下降或衰竭.
研究的目的:
- 评估免疫抑制疗法治疗儿科患者IgA脏病的益处和危害.
- 综合来自随机对照试验 (RCT) 和非随机干预研究 (NRSI) 的证据.
主要方法:
- 搜索了科克莱恩脏和移植研究登记册,直到2023年10月.
- 包括RCT和NRSI比较免疫抑制疗法与安慰剂,没有治疗,支持性护理或其他干预措施.
- 数据提取和偏差风险评估由两位作者独立进行;元分析使用随机效应模型进行.
主要成果:
- 审查包括13项研究,686名参与者 (主要是轻度Igan的儿童);偏差风险往往不清楚.
- 关于皮质类固醇治疗对蛋白尿或估计的球过率 (eGFR) 降低在IgAN儿童的影响的证据是低确定性和不确定性.
- 其他免疫抑制剂,鱼油,维生素E和桃体切除术对蛋白尿或EGFR下降有不确定的影响,对不良事件的数据有限.
结论:
- 对于在儿童中管理Igan的高质量证据显著缺乏.
- 目前的证据不支持使用类固醇,其他免疫抑制剂或桃体切除术来防止EGFR下降或蛋白尿在儿科Igan添加到辅助护理时.
- 研究结果受到研究规模较小,证据质量较低以及对危害的评估不足的限制,这使得无法将其概括为严重或非典型的IgAN病例.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
157
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
157
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
Transcytosis of IgG
2.7K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
2.7K


